GlaxoSmithKline shares ease as new boss Walmsley looks to streamline pharma business
More than 30 pre-clinical and clinical programmes will be stopped, divested or partnered out, it emerged
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 28 of 38
GlaxoSmithKline boss Walmsley unveils restructuring plan; earnings downgrade hits shares
Not entirely unexpected was the trimming of full-year earnings guidance. That said, it precipitated a modest sell-off with the stock down 1.6% in afternoon trade, wiping £1bn from the value of GSK.
FTSE 100 closes 17.5 higher as ITV plc takes podium
The blue chip index has more than made up for the miserable start to the week with a solid showing both yesterday and today...
Archive
Glaxo hoping not to make a right Horlicks of combating generics challenge
The recently-announced sale of Horlicks may be the sign of an increased focus on the drugs pipeline
Archive
Lloyds and Barclays to dominate manic week of corporate earnings
Week ahead: Lloyds, Barclays, AstraZeneca, GlaxoSmithKline, Sky, Reckitt Benckiser
FTSE 100 ends lower but European shares fare worse
London stocks were on the front foot this morning, but they quickly retreated this afternoon...
Archive
Much to ponder for GlaxoSmithKline's new boss
Next week is a big one for Emma Walmsley, GlaxoSmithKline’s newish chief executive.
GSK confirms plans to sell Horlicks in the UK and cut 320 jobs as it prioritises drugs business
GSK's new chief executive wants the company to focus on its pharmaceuticals business as it comes under increased pressure from generic drug competitors
Investments and investor services
FTSE 100 finishes over 40 points ahead with housebuilders in support
The blue chip index closed up 40.69 at 7,430 on the day
Worldpay takeover may be first of many as US firms go Brexit bargain hunting
ITV, Burberry and GlaxoSmithKline could face potential bids from international rivals as a weaker pound stokes interest in a number of UK-based firms
GlaxoSmithkline - Broker downgrade wipes £1.4bn from the value of Europe's largest drug maker
Citi has gone to ‘neutral’ from ‘buy’ on GSK shares, which it reckons are worth £17 each
Investments and investor services
FTSE 100 drifts off highs as US stocks make weak start
The FTSE 100 index was closed up 10.37 at 7,367 on Wednesday
US stocks cruise to higher finish but Tesla reverses
Wall Street shares closed mixed , but the Dow Jones added 129 in the truncated session.
Frontier IP gets boost as portfolio company Exscientia agrees AI collaboration with GlaxoSmithKline
Exscientia will use its artificial intelligence enhanced platform to identify pre-clinical drug candidates for up to 10 disease-related targets
GlaxoSmithKline and AstraZeneca among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
Liberum Capital downgrades European pharma sector to 'neutral', but remains positive on GlaxoSmithKline and AstraZeneca
The broker has been bullish on the sector since November’s US elections, in which time the sector has advanced 20%, or 12% in relative terms.
FTSE 100 rises as May's new government is DUPed
Despite the worst case scenario in the General Election, the FTSE 100 rose strongly
GlaxoSmithKline makes submissions for key HIV single-tablet treatment to both the EMA and the US FDA
The submission is for a combination of dolutegravir, developed by ViiV Healthcare and Tivicay, and rilpivirine, developed by Edurant, and Janssen Sciences Ireland UC
GlaxoSmithkline: Long-term value emerging, says broker
Berenberg’s share price target moves to £18.85 from £18.50, prompting a recommendation upgrade to ‘buy’ from ‘hold’.
Hikma's shares plunge after cutting full year revenue forecast on asthma drug launch delay
Hikma Pharmaceuticals has confirmed that it does not expect to launch its generic version of Advair this year